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Optimizing production of Fc-amidated
peptides by Chinese hamster ovary cells
Kristina Carlson1, Steven C. Pomerantz2, Omid Vafa2, Michael Naso2, William Strohl2, Richard E. Mains1
and Betty A. Eipper1,3*
Abstract
Background: Amidation of the carboxyl terminal of many peptides is essential for full biological potency, often
increasing receptor binding and stability. The single enzyme responsible for this reaction is peptidylglycine
α-amidating monooxygenase (PAM: EC 1.14.17.3), a copper- and ascorbate-dependent Type I membrane protein.
Methods: To make large amounts of high molecular weight amidated product, Chinese hamster ovary (CHO) cells
were engineered to express exogenous PAM. To vary access of the enzyme to its substrate, exogenous PAM was
targeted to the endoplasmic reticulum, trans-Golgi network, endosomes and lysosomes or to the lumen of the
secretory pathway.
Results: PAM was equally active when targeted to each intracellular location and assayed in homogenates.
Immunocytochemical analyses of CHO cells and a pituitary cell line demonstrated that targeting of exogenous PAM
was partially successful. PAM substrates generated by expressing peptidylglycine substrates (glucagon-like peptide
1-Gly, peptide YY-Gly and neuromedin U-Gly) fused to the C-terminus of immunoglobulin Fc in CHO cell lines
producing targeted PAM. The extent of amidation of the Fc-peptides was determined by mass spectrometry and
amidation-specific enzyme immunoassays. Amidation was inhibited by copper chelation, but was not enhanced by the
addition of additional copper or ascorbate.
Conclusions: Peptide amidation was increased over endogenous levels by exogenous PAM, and targeting PAM to the
endoplasmic reticulum or trans-Golgi network increased peptide amidation compared to endogenous CHO PAM.
Keywords: CHO cell, Glucagon-like peptide 1, Peptide YY, Neuromedin U, Mass spectrometry
Background
Amidated peptides act as hormones, neuromodulators
and autocrine growth factors [1, 2]. Each amidated peptide
is synthesized from a peptidylglycine precursor through
the actions of peptidylglycine α-amidating monooxygen-
ase (PAM: EC 1.14.17.3). In mice engineered to lack the
Pam gene, peptide amidating activity is not detectable and
embryos die at mid-gestation [3]. PAM contains two cata-
lytic domains, peptidylglycine α-hydroxylating monooxy-
genase (PHM) and peptidyl-α-hydroxyglycine α-amidating
lyase (PAL). The enzymes act sequentially, first converting
the peptidylglycine substrate into a short-lived peptidyl-α-
hydroxyglycine intermediate and then cleaving the C-N
bond to produce the amidated peptide and glyoxylate [2].
The active site of PHM contains two copper residues,
each of which is essential for activity. Copper is not
tightly bound to PHM and no other metal can substitute
for it. ATP7A, a P-type ATPase, transports the copper it
receives from cytosolic copper-binding chaperones into
the lumen of the secretory pathway, where the copper is
available to PHM [2, 4, 5]. Mutations in human ATP7A
cause Menkes Disease, a lethal disorder characterized by
copper deficiency [6, 7]. Mice bearing a mutation in the
Atp7a gene display similar symptoms and survive for
less than two weeks after birth. Among the many deficits
observed in these mice is the inability to produce normal
levels of amidated peptides [8]. Chelation of copper in
vitro or in vivo also leads to a reduced ability to produce
amidated peptides [9].
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The reaction catalyzed by PHM is still not fully
understood, but requires two single electron transfer
steps. Ascorbic acid (vitamin C) is present at high
levels in the secretory pathway and is generally the
source of the reducing equivalents needed to support
peptide amidation [2]. In the absence of ascorbic acid
in cell culture systems, peptide amidation fails to
occur and other single electron donors or reducing
agents (e.g. NADH, NADPH, dithiothreitol, dopa-
mine), cannot fully substitute for ascorbate [10].
Previous studies of the production of amidated pep-
tides in cell lines have had mixed results. Using trans-
fected CHO and COS7 cells, Takahashi et al. [11] found
very efficient amidation of salmon calcitonin (C-terminal
Pro-NH2), while Hayashi et al. [12] reported that amida-
tion of gastrin (C-terminal Phe-NH2) was efficient in
CHO cells but not in COS7 cells. These results are
puzzling, since peptides terminating with –Phe-Gly are
far better substrates for PAM that peptides terminating
with –Pro-Gly, using test tube assays and purified
enzyme [1]. Johansen et al. [13] showed that amidation
of NPY (C-terminal Tyr-NH2), another excellent PAM
substrate, only proceeded to 50–80 % completion in
different CHO cell lines. Work using neuroendocrine
lines which express prohormone convertases along with
PAM consistently always shows complete amidation
after transfection of preprohormone precursor cDNAs
[14–18]. Thus, it is difficult to predict which peptide
precursors will be efficiently amidated in which cell
lines, especially if the goal is to achieve essentially 100 %
amidation without extraneous or unwanted endoproteo-
lytic cleavages.
In an attempt to prolong the half-lives of amidated
peptides, we engineered CHO cells to produce Fc-
peptidylglycine fusion proteins in the absence and
presence of exogenous PAM; both soluble and integral
membrane forms of PAM were tested for their ability
to support Fc-peptidylglycine fusion protein amidation
in CHO cells [19]. The extent of amidation observed
varied from 25 to 90 % for different Fc- peptidylgly-
cine substrates, but the expression of exogenous PAM
always increased the amidation of Fc- peptidylglycine
substrates [19]. The extent of amidation never reached
100 %, which would be essential for many pharma-
cotherapeutic applications. It is clear that PAM activ-
ity is rate-limiting for peptide amidation in CHO cells,
since increasing PAM increased amidation [19], while
decreasing PAM lowered the extent of amidation [20].
Since PHM requires both copper and ascorbate to func-
tion, we explored three ways to improve the ability of
CHO cells to secrete amidated Fc-fusion peptides. First,
we used known targeting signals to try to localize integral
membrane PAM to different subcellular locations in CHO
cells expressing an Fc-GLP1-Gly fusion protein. Second,
we added exogenous copper or a copper chelator to the
culture medium to vary the availability of copper. Third,
we added exogenous ascorbate to the culture medium to
see if an increase in reducing equivalents would improve
Fc-peptidylglycine amidation.
Results
Design of targeting vectors
The isoforms of PAM identified in rat, mouse, human and
Chinese hamster encode similar soluble and integral
membrane proteins. Each isoform includes an N-terminal
signal sequence, but the largest isoforms also include a
transmembrane domain, generating type I integral mem-
brane proteins. The trafficking of rat PAM1 has been
studied extensively in both endocrine cells, which generate
soluble PHM from membrane PAM, and in cells which
lack the proteases required to make this cleavage. PAM1
cycles between the trans-Golgi network (TGN) and the
plasma membrane, returning to the TGN after endocyto-
sis [21]. When expressed in endocrine cells, the PHM and
PAL catalytic cores are efficiently packaged in secretory
granules; when expressed in CHO cells, both active
enzymes are secreted into the medium.
We used well characterized trafficking signals to try to
target PAM to different subcellular locations in CHO
cells producing an engineered PAM substrate, Fc-AP-
GLP1-Gly [19]. To facilitate identification of cells ex-
pressing PAM and analysis of trafficking, we used EGFP-
tagged rat PAM (Fig. 1a). Since we wanted to use the
same tag for each targeting vector, EGFP was inserted
into the linker region that separates PHM from PAL in
PAM1; 55 amino acids of the linker region were replaced
by EGFP, with no deleterious effect on either enzymatic
activity [22]. The paired basic cleavage site present in
the linker region, which allows endoproteolytic cleavage
of PAM1 in neurons and endocrine cells, was eliminated
in PAM/GFP. For comparison, a soluble GFP-tagged
PAM protein was generated by truncating PAM/GFP
after the catalytic core of PAL (PAM820s/GFP).
Well characterized targeting signals known to direct
proteins to the endoplasmic reticulum (ER), TGN, endo-
somes (Endo) and lysosomes (Lyso) were used (Fig. 1a).
The cytosolic domain of PAM was replaced by the cyto-
solic domain of ERGIC-53, generating PAM/ER [23].
GalT, a type II integral membrane protein, is targeted to
the TGN by its N-terminal transmembrane and juxta-
membrane region [24]; the signal sequence and pro-
region of soluble PAM820s/GFP were replaced by this
region of GalT, generating PAM/TGN, a putative type II
membrane protein. For endosomal targeting, the trans-
membrane and cytosolic domains of PAM were replaced
with the corresponding regions of the cation independ-
ent mannose-6-phosphate receptor in PAM/Endo [25].
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The transmembrane and cytosolic domains of LAMP1
were used in a similar manner to create PAM/Lyso [26].
To evaluate the catalytic activity of the targeted PAM/
GFP proteins, each was expressed transiently. Cell ex-
tracts were prepared for analysis of protein integrity
(Fig. 1b) and PHM catalytic activity (Fig. 1c). Western
blot analysis using an antibody to the PHM domain re-
vealed a single major protein of the expected molecular
mass in each lysate. To compare the specific activities of
the targeted proteins, PHM activity in each lysate (pmol
product/mg/h) was normalized to the amount of PHM
protein (arbitrary OD units/mg); data for each targeted
PAM protein were normalized to the value for PAM/
GFP analyzed at the same time (Fig. 1c). Normalized to
PHM protein, the catalytic activities of the targeted
PAM proteins did not differ significantly.
Analysis of cells expressing targeted PAM proteins
The goal of this work was to express Fc-fusion peptides in
cells with no prohormone convertases (CHO cells), but
there are few good markers of intracellular organelles in
CHO cells, while pituitary cells have been studied exten-
sively. Since so much is known about PAM trafficking in
pituitary cells [21, 27], each GFP-tagged targeted PAM
protein was transiently expressed in AtT-20 corticotrope
tumor cells, where its localization could be compared to
that of PAM/GFP and established markers for cis-Golgi
(GM130), TGN (TGN38), secretory granules (ACTH)
and lysosomes (LAMP1). PAM/ER accumulated in the
perinuclear region (Fig. 2a). GFP and GM130 staining
overlapped extensively, but examination of the merged
image revealed that the patterns were not identical
(Fig. 2a); PAM/ER staining was also distinguishable
from TGN38 staining (Fig. 2b) and the small amount of
diffusely distributed PAM/ER staining was distinct from
staining for secretory granule granules or lysosomes.
Much like PAM/ER, PAM/TGN was localized to the peri-
nuclear region, overlapping extensively with GM130 and
TGN38 (Fig. 2b). Examination of the merged images sug-
gested that PAM/TGN staining in the perinuclear region
overlapped more with TGN38 than with GM130. PAM/
Lyso staining concentrated in the perinuclear area and in
vesicles distributed throughout the cytosol; based on their
failure to stain with antisera to LAMP1, these vesicles
were not lysosomes (Fig. 2c). Based on their localization
patterns in AtT-20 cells, the trafficking signals appended
to PAM were only partially successful in altering its sub-
cellular localization. Significantly more vesicular staining
was observed in cells expressing PAM/Endo (Fig. 2d).
Vesicular staining of PAM/Endo was not coincident with
staining for LAMP1 (Fig. 2e) or ACTH (not shown). In
the perinuclear region, PAM/Endo staining was coincident
with TGN38 staining (Fig. 2e), but extended beyond the
structures enriched in TGN38. The fact that both
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Fig. 1 Targeted PAM proteins. a. Diagram of PAM1 and GFP-tagged targeted PAM proteins. The regions of ERGIC-53, Galactosyl Transferase 1, cation
independent mannose-6-phosphate receptor and LAMP1 used to redirect rat PAM/GFP are indicated. PAM820s/GFP was truncated immediately after
the catalytic core of PAL. b. pEAK Rapid cells, a derivative of hEK293 cells, were transiently transfected with vectors encoding the indicated proteins.
After 24 h, cell extracts were prepared using 20 mM NaTES, 10 mM mannitol, 1 % TX-100, pH 7.4; aliquots were subjected to Western blot analysis and
visualized using an antibody to the PHM domain. c. PHM activity was measured in each cell lysate and normalized to the amount of PHM protein
detected on the Western blot; the PHM activity/PHM protein ratio for PAM/GFP was set to 1.0 for each of three experiments; error bars show the
standard deviation. None of the differences were significant
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luminal domains of PAM are efficiently packaged into
secretory granules, with no added routing information
[28], presumably limits the extent to which membrane
PAM can be re-directed.
Analysis of stably transfected CHO cell lines expressing
the Fc-GLP1-Gly fusion protein and a targeted PAM
protein
Since each targeting vector generated an active PAM
protein, we next attempted to generate CHO cell lines
stably expressing a targeted PAM protein along with
substrate by introducing the targeted PAM protein into
CHO cells stably expressing Fc-GLP1-Gly. The sequence
of GLP1-Gly was appended to the C-terminus of the Fc
region of human IgG1, separated by an (Ala-Pro)10 linker
and a human rhinovirus protease cleavage site (LEVLFQ/
GP) [19]. We obtained stable CHO cell lines expressing
the Fc-GLP1-Gly fusion protein and three of the targeted
PAM proteins, but were unable, despite multiple attempts,
to derive a stable line expressing PAM/Lyso. Since PAM/
GFP localization resembled that of PAM1, a previously
generated CHO line expressing Fc-GLP1-Gly and PAM1
was analyzed for comparison [19].
Western blot analysis of cell extracts revealed the pres-
ence of proteins of the expected mass; the targeted PAM
proteins were recognized by antibodies to both PHM and
GFP (Fig. 3a). Cell lysates prepared in buffer containing
1 % TX-100 were assayed for PHM and PAL activity
(Table 1). Enzymatic activity was five to 10-fold higher in
the targeted PAM lines and in the previously established
PAM1 line than in the Fc-GLP1-Gly fusion protein cell
line, which expresses endogenous CHO PAM. PHM
secretion rates for the different lines were determined by
assaying PHM activity in spent medium and ranged from
5 %/h for PAM/ER and PAM/TGN to 11 %/h for PAM/
Endo and 22 %/h for PAM1. Cell content and secretion of
Fc-GLP1-Gly fusion protein were evaluated by Western
blot (Fig. 3b) and quantified (Table 1); Fc content and se-
cretion rate were similar in each of the lines.
Localization of targeted PAM proteins in stable CHO cell
lines
The steady state localization in CHO cells of each targeted
PAM protein was compared to that of recognized subcellu-
lar markers for the endoplasmic reticulum (calnexin), cis-
Golgi (giantin) and endosomes (early endosomal antigen 1,
EEA1). PAM/ER accumulated in puncta surrounding the
nucleus; staining for calnexin revealed the expected widely
distributed reticular pattern, with little overlap with PAM/
ER (Fig. 4a, b). Staining for PAM/ER showed significant
a
b
d e
c
Fig. 2 AtT-20 cells expressing targeted PAM constructs. a. AtT-20 cells were fixed and permeabilized 24 h after transfection; targeted PAM proteins were
visualized using antibody to GFP and a FITC-tagged secondary antibody (green in merged images and white in panels showing GFP alone); subcellular
markers were visualized using a Cy3-tagged secondary antibody (red) and nuclei were stained using Hoechst (blue). Cells expressing PAM/ER were stained
for GM130 (a); three cells are shown, but only two were transfected. Cell expressing PAM/TGN were stained for TGN38 (b). Cells expressing PAM/Lyso were
stained for LAMP1 (c). Cells expressing PAM/Endo were stained for GM130 (d) or LAMP1 (e). Epifluorescence images were taken using a 60X oil immersion
lens; scale bar, 20 μm
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overlap with compartments containing giantin, but little
overlap with EEA1 containing compartments (not shown).
PAM/TGN also accumulated in puncta surrounding the
nucleus, overlapping compartments containing giantin
(Fig. 4c, d); very little dispersed vesicular staining was ob-
served. Although PAM/Endo also accumulated in puncta
surrounding the nucleus (Fig. 4e), its distribution was more
widespread, with tiny puncta of staining distributed
throughout the cell. Co-localization of PAM/Endo and
EEA was readily apparent in these widely dispersed ves-
icular structures (Fig. 4f); little overlap was observed with
calnexin positive compartments, and only partial overlap
with giantin positive compartments was observed (not
shown). Unlike the separation observed between PAM/
TGN or PAM/Endo and a cis-Golgi marker (GM130) in
the transiently transfected AtT-20 cells, extensive overlap
of both PAM/TGN and PAM/Endo with a cis-Golgi
marker (giantin) was observed in the stably transfected
CHO cell lines.
Analysis of Fc-GLP1 fusion protein glycosylation and
amidation
Fc-GLP1 fusion proteins secreted by the PAM1 and tar-
geted PAM CHO cell lines were purified using HiTrap Pro-
tein A cartridges. The Fc region of the Fc-peptidylglycine
substrate includes a single N-linked oligosaccharide. Evalu-
ation of the glycan distribution of Fc-AP-GLP1 purified
from CHO cells expressing PAM/TGN, PHMcc (PAM
a
b
Fig. 3 Stably transfected CHO cell lines expressing targeted PAM proteins. a. Western blots for PHM, GFP and γ-adaptin. b. Western blot for Fc in
cell extracts (CE; 15 μg protein) and spent media; human IgG was analyzed as a control
Table 1 PAM and AP-GLP1-Fc: expression levels and secretion rates. The indicated cell lines were extracted as described in the legend
to Fig. 1 and assayed for PHM and PAL activity; data from multiple dilutions of at least 3 independent extracts were averaged and standard
errors reported. PHM secretion ( % content/h) was calculated by assaying PHM activity in a 16 h medium collection. Fc levels in cell extracts
and spent media were determined by Western blot and used to calculate cell content of Fc and Fc secretion rate
Cell line PHM pmol/μg/h PAL pmol/μg/h PHM secretion % content/h Fc, μg/mg cell protein Fc secretion % content/h
AP-GLP1 (Parental line) 0.17 ± 0.01 0.8 ± 0.3 18 ± 4.8 1.3 ± 0.04 8.0 ± 1.4
AP- GLP1 1.8 ± 0.15 17.1 ± 2.0 4.6 ± 1.1 1.2 ± 0.11 6.9 ± 2.4
PAM/ER
AP-GLP1 1.2 ± 0.2 10.5 ± 3.4 4.5 ± 1.2 2.3 ± 0.5 17.8 ± 1.7
PAM/TGN
AP-GLP1 0.90 ± 0.12 17.7 ± 4.8 11.0 ± 2.5 1.4 ± 0.1 10.0 ± 2.6
PAM/Endo
AP-GLP1 1.5 ± 0.21 13 ± 10 22 ± 2.8 2.3 ± 0.2 20.4 ± 2.3
PAM-1
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monooxygenase catalytic core; [2] ), PAM1 and PAM/Endo
was determined by reverse-phase HPLC-MS intact mass
analysis (not shown). The patterns were complex, perhaps
indicating premature Fc-GLP1 fusion protein secretion
from the medial Golgi [29] and/or interference with normal
Fc glycan processing by the engineered PAM proteins.
In order to facilitate analysis of α-amidation, the puri-
fied fusion proteins were cleaved using the engineered
site inserted into the linker region connecting human
IgG1 to GLP1-Gly and the mass of the released peptide
was determined by mass spectroscopy (Table 2). The ex-
pression of exogenous PAM increased the extent of peptide
amidation from 71 % in cells only expressing endogenous
CHO PAM to 90 % or more in all of the lines synthesizing
exogenous PAM (all p ≤ 0.011). PAM-TGN and PAM-ER
cells produced amidated GLP1 significantly more effectively
than did PAM1 cells (p < 0.05), which suggests that slowing
the progression of membrane PAM through the cell im-
proves the efficiency of the amidation process, achieving
one goal of these studies.
To expedite analysis of Fc-GLP1-Gly amidation, we ex-
plored the use of enzyme-linked immunoassays (EIA). A
solid phase EIA for GLP1 was shown to be specific for the
amidated peptide (Fig. 5a); neither the GLP1-Gly precur-
sor nor a peptide terminating with -Arg-OH instead of –
Arg-NH2 was recognized. Use of the GLP1-NH2 EIA to
assess Fc-GLP1 amidation in spent medium was validated
by exposing CHO cells expressing Fc-GLP1-Gly without
or with PAM1 to bathocuproinedisulfonate (BCS), a cell
impermeant copper chelator specific for Cu(I) (Fig. 5b)
[30]. After overnight (16 h) incubation of cells with 50 μM
BCS, the molar ratio of GLP1-NH2 to Fc dropped more
than 20-fold for both cell lines, demonstrating the utility
of the EIA. Notably, secretion of the Fc-GLP1 fusion pro-
tein was not affected by the presence of BCS (Fig. 5c).
We next compared the ability of different concentra-
tions of BCS to limit the amidation of Fc-GLP1 pro-
duced in CHO cells lacking exogenous PAM and in
CHO cells expressing PAM1 (Fig. 5d). In both lines, Fc-
GLP1 amidation was almost entirely prevented by incu-
bation of the cells with medium containing 10 μM BCS.
The sensitivity of endogenous CHO cell PAM and ex-
ogenous rat PAM1 to BCS was similar.
Analysis of Fc-NMU and Fc-PYY fusion protein amidation
Since Fc-NMU-Gly and Fc-PYY-Gly are amidated less ex-
tensively than Fc-GLP1-Gly when expressed in CHO cells
[19], we evaluated the ability of commercially available
a
b d f
c
e
Fig. 4 Subcellular localization of targeted PAM proteins. The indicated CHO cell lines were fixed, permeabilized and stained simultaneously with
antisera to GFP (visualized using a FITC-tagged antibody) and to the indicated subcellular markers (visualized using a Cy3-tagged antibody). Cells
expressing PAM/ER were stained for GFP and calnexin (a) or GFP alone (b). Cells expressing PAM/TGN were stained for GFP and giantin (c) or for
GFP alone (d). Cells expressing PAM/Endo were stained for GFP and EEA1 (e) or for GFP alone (f). Epifluorescence images were taken using a 60X
oil immersion lens
Table 2 Mass spectroscopic determination of amidation of GLP1
by various PAM proteins. Fc-GLP1 secreted by the indicated cell
lines was purified using Protein A; after cleavage with the Rhinovirus
protease [19], products were subjected to mass spectroscopic
analysis; data for Fc-AP-GLP1 secreted by CHO cells expressing
PAM1, PAM/ER, PAM/TGN and PAM/Endo are shown. Mean ± SEM
PAM source % Amidation
Endogenous 71.4 ± 0.3
PAM1 89.5 ± 1.5
PAM/ER 93.2 ± 1.3
PAM/TGN 95.4 ± 2.2
PAM/Endo 92.6 ± 3.1
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EIA kits for these peptides to distinguish the amidated
peptide from its precursor (Fig. 6). The NMU EIA recog-
nized NMU8 and NMU25 equally, even though only the 8
C-terminal amino acids of NMU25 are present in NMU8.
Longer NMU peptides with a –Gly residue appended to
the –Asn that is normally amidated gave only partial
cross-reactivity (Fig. 6a). Consistent with the fact that
mass spectroscopic analysis revealed that ~70 % of the Fc-
NMU-Gly secreted by CHO cells expressing only en-
dogenous PAM was amidated [19], samples of spent
medium from CHO cells expressing Fc-NMU-Gly with
the Ala-Pro or the Gly-Gly-Ser linker generated competi-
tion curves parallel to those of amidated NMU. As for Fc-
GLP1 amidation, growth of CHO cells in medium con-
taining increasing concentrations of BCS eliminated the
ability of the spent medium to generate competition
curves parallel to that of the NMU standard; instead, par-
tial competition was observed, with a curve resembling
that generated by the GS-NMU-Gly peptide (Fig. 6a,
right). Based on these observations, we concluded that
amidated Fc-NMU fusion protein was no longer being
secreted.
We next assessed the ability of an EIA for PYY to dis-
tinguish between amidated PYY and PYY-Gly (Fig. 6b).
As for NMU, the assay for PYY showed partial cross-
reactivity with PYY-Gly. Samples of spent medium from
CHO cells expressing Fc-PYY-Gly generated curves par-
allel to those of amidated PYY and easily distinguishable
from those of non-amidated PYY-Gly. Spent medium
samples from CHO cells expressing Fc-PYY-Gly and
kept in medium containing BCS generated competition
curves more parallel to those generated by PYY-Gly than
the full competition curve generated by amidated PYY
(Fig. 6b); inclusion of 50 μM BCS in the medium largely
abolished secretion of the fully reactive PYY peptide.
Enhancing Fc-peptidylglycine amidation
Since PAM requires copper and consumes ascorbate, we ex-
plored the possibility that providing increased amounts of
either required component might increase the ability of CHO
cells to secrete amidated fusion protein. The concentration of
copper in DMEM/F-12 is 5 nM (http://www.thermofisher.
com/us/en/home/order/cell-culture-transfection-reagents.html).
Although cultured cells maintained in concentrations of
CuSO4 as high as 10 μM grow normally [30], addition of
this level of exogenous CuSO4 to spent medium from
CHO cells producing PHMcc demonstrated that PHMcc
was rapidly inactivated (data not shown). We therefore
asked whether a more modest increase in Cu levels in the
culture medium promoted amidation (Fig. 7a). CHO cells
a b
c d
Fig. 5 GLP1-amide enzyme immunoassay. a. Validation of GLP1-amide assay using synthetic peptides. The amidated peptide representing the C-terminal
half of GLP1 diluted in parallel with the GLP1-NH2 standard, as did culture medium from all the CHO cell lines producing Fc-GLP1-Gly (not shown).
Both the Gly-extended GLP1 and the des-Gly peptide (terminating in Arg) showed no cross-reactivity in the assay. b. CHO cells expressing AP-GLP1-Gly
(no exogenous PAM) or AP-GLP1-Gly and PAM1 (PAM1) were plated onto 12-well plates and incubated with control medium or medium containing
50 μM BCS for 16 h; spent media and cells were harvested and subjected to Western blot analysis for Fc and EIA for GLP1-NH2. The molar ratio of GLP1-
NH2 to Fc is shown. c. Western blot for Fc from one of the experiments included in (c), demonstrating the lack of toxicity of the BCS treatment. d. Dose
response for BCS, demonstrating the similar effect of BCS on the ability of endogenous CHO PAM and exogenous PAM1 to produce amidated GLP1-NH2;
average of 2 assays
Carlson et al. BMC Biotechnology  (2015) 15:95 Page 7 of 12
expressing Fc-peptide-Gly were incubated in DMEM/F-12
medium containing 0, 5 or 20 nM additional CuSO4 for
16 h. Based on EIA data and Western blot analysis of the
secreted product, the extent of amidation of Fc-GLP1, Fc-
PYY and Fc-NMU was not altered by the addition of
CuSO4.
Although CHO cells express gulonolactone oxidase
(XM_003505165.1) and thus do not have the same gen-
etic block to ascorbate synthesis present in humans and
some other mammals, we next asked whether provision
of additional ascorbate could increase the extent of Fc-
peptide amidation. Cells were maintained in medium
containing 0 or 50 μM ascorbate for 16 h; cells and
media were harvested and EIAs and Western blots were
carried out. The provision of additional ascorbate had
no significant effect on the extent of amidation of Fc-
GLP1-Gly, Fc-NMU-Gly or Fc-PYY-Gly (Fig. 7b). Blood
levels of ascorbate are around 50 μM [31], and 50 μM
ascorbate restores peptide amidation in rat pituitary cells
maintained in serum-free medium [32].
Discussion
Chinese hamster ovary cells are used to produce >70 %
of all biopharmaceuticals [20]. It is now clear that CHO
cells producing monoclonal antibodies catalyze their α-
amidation to varying extents [20, 33–35]. Unlike mono-
clonal antibodies, where amidation could impair optimal
functionality [20], we investigated methods that would
maximize the amidation of Fc-peptidylglycine fusion
proteins, wherein amidation would increase the bio-
logical potency of the product peptide. The only enzyme
which can amidate the COOH-terminus of peptides is
PAM [36, 37]. In most neuroendocrine cells the extent
of peptide amidation is close to 100 %, even with only
one functional allele of PAM [38, 39]. In neuroendocrine
cells, most peptide amidation occurs in large dense core
vesicles, which are stored for periods of many days,
allowing plenty of time to complete the amidation
process [40]. CHO cells lack such long-term storage sites,
so PAM was targeted to various intracellular sites in an at-
tempt to increase the access of PAM to its peptidylglycine
substrates and maximize the extent of amidation.
Targeting PAM to different locations in the cell turned
out to be more difficult than anticipated. When pre-
ceded by the PAM signal sequence, expression of the
protease resistant catalytic cores of PHM and PAL yields
active enzyme that is rapidly secreted by CHO cells [41]
or efficiently stored in the secretory granules of AtT-20
a
b
Fig. 6 NMU and PYY enzyme immunoassays require amidation for full cross-reactivity. a. Characterization of NMU-amide assay using synthetic peptides.
Left: the medium from PAM/820 s cells exhibited a dilution pattern parallel to the amidated standard peptide. Synthetic NMU-8-NH2 (Bachem) was almost
identical to the full 25-residue NMU-NH2 in the assay (not shown). By contrast, the Gly-extended synthetic peptide and CHO medium from PAM/820 s
cells after BCS treatment showed similar flat, partial dilution curves. Right: BCS in a dose-dependent manner inhibited the amidation of NMU by the PAM/
820 s cells, using data from 1 to 6 μl of medium. Secretion of Fc-NMU was not affected (not shown). b. Left: Characterization of PYY-amide assay using
synthetic peptides. Left: medium from CHO cells expressing PAM1 diluted in parallel with the authentic PYY-NH2 standard, while the Gly-extended
peptide and medium from BCS-treated cells exhibited a much flatter dilution profile. Right: 50 μM BCS inhibited amidation of PYY, using data from 0.5
to 2 μl medium. For both NMU and PYY, data from several assays were normalized using their respective standards to enable the comparisons
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cells [28]. In contrast, PAM1 is largely localized to the
TGN area in both cell types; in the perinuclear region of
AtT-20 cells, PAM1 has been identified in vesicular
components of both the endocytic and biosynthetic
pathways [42]. Truncation of PAM1 immediately after the
stop transfer signal that follows its transmembrane do-
main (PAM1/899) yields a protein that cannot undergo
endocytosis and accumulates on the cell surface [43]; this
observation highlights the essential role played by endocy-
tic trafficking in localizing membrane PAM. The fact that
PAM1 fused to ER, endosomal or TGN targeting signals
localized primarily to the perinuclear trans-Golgi network
region is consistent with a major role for the luminal do-
mains of PAM in controlling its endocytic trafficking [44].
A strong influence of the luminal domain on efforts to
redirect proteins to novel subcellular locations is well
established [25]. The specific activity of PHM did not
differ when it was part of PAM/TGN, a TypeII integral
membrane protein or part of PAM1, PAM/ER, PAM/Endo
or PAM/Lyso, which are all Type I integral membrane
proteins (Fig. 1c).
Each method for determining the extent of peptide ami-
dation has its advantages and drawbacks. The mass spec-
trometry approach provides data for both the nonamidated
and amidated peptide in a single run, but the relative recov-
ery of the two peptides (−Gly and –NH2) is difficult to
assess without synthetic standards for every case. The EIA
is very selective for the amidated end (especially the GLP1-
NH2 EIA) and Western blots allow assessment of protein
stability. The large dynamic range of the Genegnome facili-
tates analysis, but the dilutions needed for the EIA compli-
cate the analysis.
Our data suggest that PAM speeds the rate of trafficking
of the Fc-peptides through the secretory pathway, at least
for the PAM1 and PAM/TGN lines (Table 1). This change
may parallel the changes seen in the trafficking of soluble
products derived from pro-opiomelanocortin in pituitary
corticotropes, where expressing PAM1 increases the rate
of basal secretion [45]. Like chromogranin A, PHM and
PAL are efficiently targeted to secretory granules in corti-
cotrope tumor cells. While expression of exogenous chro-
mogranin A in non-endocrine cells causes the formation
of granule-like structures [46], neither expression of
PHMcc, PAM820s or PAM1 caused granule formation in
CHO cells.
Although extensive amidation of the Fc-AP-GLP1-Gly
substrate occurred in cells expressing only endogenous
CHO PAM, expression of exogenous PAM1 or targeted
PAM did significantly increase the percentage of sub-
strate that was amidated. Efforts were made to deter-
mine what factors control the extent of amidation of the
Fc-peptide substrates. As expected, removal of copper
blocked amidation. Although copper-dependent, PAM
does not bind copper tightly, making it susceptible to
copper chelators. This raised the possibility that increas-
ing copper delivery to PAM could increase peptide amida-
tion. However, the nanomolar levels of copper in DMEM/
F12 (5 nM) appear to be adequate; raising the copper
a
b
Fig. 7 Varying copper and ascorbate concentrations. a. Copper. Adding small amounts of CuSO4 did not increase amidation of GLP1 by endogenous
CHO cell PAM or by exogenous PAM1, the amidation of NMU by exogenous PAM/820 s, or the amidation of PYY by exogenous PAM1. The base medium
contained 5 nM Cu (Life Technologies website). b. Ascorbate. Adding a concentration of ascorbate equivalent to normal plasma levels (AscA: 50 μM) [56]
did not increase amidation of GLP1, NMU or PYY by the same cell lines as in (a). The base medium did not contain ascorbic acid. For all three peptides,
data from several assays were pooled
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concentration in the medium five-fold had no effect on
the extent of amidation. Higher levels of copper inacti-
vated PHM and oxidized the secreted Fc peptides.
Since CHO cells express gulonolactone oxidase, they
can synthesize ascorbate and are not dependent on acquir-
ing it from the medium; consistent with this fact, supply-
ing additional (exogenous) ascorbate did not increase the
extent to which any of the Fc-peptidylglycine substrates
was amidated. In contrast, all human cells and rodent
neurons and endocrine cells rely on ascorbate taken up
from their environment. DMEM/F12 does not contain
ascorbate, and peptide amidation by rat pituitary cells
maintained in serum-free medium is dependent on ex-
ogenous ascorbate [32].
Conclusions
Elimination of CHO cell PAM expression and activity
would avoid unintended amidation (e.g. of antibodies),
which may have a therapeutic benefit (if amidated anti-
bodies are mildly antigenic, for example) [20]. However,
there are apparently no adverse consequences of having
a portion of the monoclonal antibodies amidated, since
that is also true of antibodies produced endogenously
[33, 35]. The point of these studies was to determine
whether CHO cells expressing PAM and a Fc-peptide
substrate could be made to amidate a high percentage of
the Fc-fusion peptide, for the purpose of producing bio-
pharmaceuticals, and the answer is quite clearly in the
affirmative. The broad specificity of PAM and its ability
to function when traversing the cell surface or when tar-
geted to the endocytic pathway raise the possibility of
using PAM to catalyze other modifications of exogen-
ously supplied substrates.
Methods
Molecular biology
The pCIS vector encoding rPAM1 was described [47]. To
construct a pCI.neo vector encoding PAM/GFP, residues
D408VH—RDR462 of rPAM1 were replaced by a linker
(EDPRPVAT) followed by enhanced green fluorescent
protein (EGFP), which has the non-dimerizing A206K mu-
tation [22]. A stop codon was introduced into rPAM1 and
PAM/GFP after -RSV820 to produce the soluble proteins
PAM820s and PAM820s/GFP, respectively. Residue
-SGR911 of PAM/GFP was fused to -GKKAA (modeled
after the ER retention signal in ERGIC-53) [23] to yield
PAM/ER. PAM/TGN was created by inserting residues
M1RL—PGP110 of the TGN-localized enzyme hGalactosyl
Transferase 1 (AAH45773.1) immediately before residues
S42FS- of PAM820s/GFP [24]. PAM/Endo was made by
fusing PAM820s/GFP through an Xba1 linker encoding –
SR- to residues S184HS—LPM277 of hCation Independent
Mannose-6-Phosphate Receptor (NP_002346.1), which
traffics through the endosomal compartment [25]. PAM/
Lyso was created in a similar manner, with the Xba1 linker
connected to D378EN—QTI417 of hLAMP-1 (NP_00555
2.3), an enzyme targeted to lysosomes [48]. All constructs
were verified by DNA sequencing. The Fc-linker peptide
substrates with blasticidin drug selection were described
[19], and contain linkers (GS: (GGS)6-GGLEVLFQGP and
AP: (AP)10-LEVLFQGP) between the Fc and the peptide
substrates.
Cell culture
pEAK Rapid cells (hEK-293 derivative; Edge Biosystems,
Gaithersburg MD) were transiently transfected using
Lipofectamine 2000 (Invitrogen Life Technologies,
Grand Island, NY) as described [49]. To test the efficacy
of the targeting signals, vectors encoding targeted PAM
were expressed transiently in AtT-20 corticotrope tumor
cells plated onto coverslips coated with poly-L-lysine
followed by NuSerum (Corning, Corning NY). Cells on
coverslips in 24-well dishes were transfected with 1 μg
DNA complexed with 2.5 μl Lipofectamine 2000. Cells
were fixed with 4 % formaldehyde in phosphate buffered
saline approximately 24 h after transfection.
Stable clones of CHO cells expressing PAM1 and
PAM820s from the pCIS vector were selected in Alpha-
MEM with dialyzed fetal bovine serum [2]. Stable clones
of CHO cells expressing PAM/GFP, PAM/ER, PAM/
TGN and PAM/Endo encoded by a pCI.neo vector were
established in DMEM/F-12 containing 10 % fetal bovine
serum and 0.5 mg/ml G-418 [50]. Stable clonal PAM/
Lyso lines were never successfully selected. Other cell
lines expressing Fc-peptide precursor fusions were estab-
lished previously [19]. For each clonal line examined and
reported in depth, there were 2–6 additional lines with
lower expression levels that exhibited similar properties.
Medium levels of Cu and ascorbate were adjusted
using 100-500X stocks of ascorbate, CuSO4, and batho-
cuproinedisulfonic acid (BCS); stocks were sterile filtered
and added to the medium 24 h before the start of a 16 h
collection. Secretion of Fc-fusion peptides was detected
using a peptide-specific Enzyme ImmunoAssay (EIA)
and by Western blot analysis for Fc.
Biochemistry
PHM and PAL activity were assayed in duplicate using
[125I]-labeled substrate (Acetyl-Tyr-Val-Gly), 0.5 μM un-
labeled substrate and multiple sample dilutions as de-
scribed [51]. Western blots were performed as described
using antisera to PHM (JH1761), GFP, γ-adaptin (#61038;
BD Transduction Laboratories) or human Fc and HRP-
tagged secondary antisera [19].
Enzyme ImmunoAssay kits specific for the indicated
peptides were purchased from Bachem (Torrance, CA):
GLP1(7–36) amide [S-1141]; GLP1 (7–37)Gly [S-1216];
Neuromedin U-25 [S-1253]; PYY [S-1151]. Spent medium
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samples were diluted 1:5 in EIA buffer before being
assayed. Samples were further diluted into buffer based on
Western blot data for Fc concentration. Dilutions of the
standard peptide for each assay were prepared per the
manufacturer’s instructions. One well did not receive any
standard peptide and defined maximum binding. One well
did not receive antibody and defined minimum binding.
Standards and samples were added to strips of a 96-well
plate coated with antibody to rabbit IgG in a final volume
of 50 μl. Dilute antibody (25 μl) was added to each well
except the no antibody control and samples were incu-
bated for 1 h at RT. Biotinylated peptide (25 μl) was added
to each well and samples were incubated for 2 h at RT.
Wells were washed five times with 200 μl buffer.
Streptavidin-tagged HRP (100 μl of a 1:600 dilution in buf-
fer) was added to each well and the samples were incu-
bated for 1 h at RT. After washing again as described,
substrate (100 μl of TMB diluted three-fold with 100 mM
Na acetate, pH 5.0) was added. After ~4 min, the reaction
was stopped by adding 110 μl HCl (2 M) to each well and
absorbance was read at 450 nm using a Wallac plate
reader (Victor 1420). Peptide concentrations in unknown
samples were calculated using the weighted logit-log
method [52]. Analysis of synthetic GLP1-NH2 and GLP1-
Gly revealed that the GLP1 (7–37)Gly [S-1216] assay
cross-reacted fully with GLP1-NH2, so this assay was not
used further.
Immunostaining
Four-well chamber slides [Thermo Scientific, Waltham,
MA] were coated with poly-L-lysine (0.1 mg/ml) to en-
hance cell attachment. Cells were fixed with 4 % formalde-
hyde [J.T.Baker, Center Valley, PA] in PBS (20 min) or with
ice cold MeOH (20 min) depending on the antibody used.
Antisera to PAM were generated in-house and were
described previously: mouse monoclonal 6E6 to the
cytosolic domain (1:10 dilution of spent medium) [53];
JH1761, rabbit antibody to purified recombinant PHM
(1:1000) [54]; JH629, rabbit antibody to exon 16
(1:1000) [55]; CT267, rabbit antibody to the C-terminus
of PAM (1:1000) [50].
The following subcellular marker antibodies were used:
calnexin (1:500; #208882; Millipore, Billerica, MA); GFP
(1:1000; #75–131; NeuroMab, Davis, CA); giantin (1:1000;
ab24586; Abcam, Cambridge, MA); early endosomal anti-
gen 1 (EEA1) (1:500; #324610; Calbiochem, Billerica, MA);
human Fc (1:4000; #309–001–008; Jackson ImmunoRe-
search, West Grove, PA); human Fc (1:100; #9042–01;
SouthernBiotech, Birmingham, AL). Secondary antibodies
(all from Jackson ImmunoResearch, West Grove, PA) were:
FITC-tagged donkey anti-mouse (1:500; #715–096–151);
FITC-tagged donkey anti-rabbit (1:500; #715–096–151);
Cy3-tagged donkey anti-rabbit (1:2000; #711–166–152).
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